GET THE APP
ISSN: 2168-9857
+44-20-4587-4809
Marc R Matrana Precision Cancer Therapies (Phase I ) Program, Ochsner Cancer Institute, Tanzania
Editorial FDA Approves an Adjuvant Targeted Therapy for Post-Surgery RCC Patients, but Questions and Clinical Challenges Remain Author(s): Marc R MatranaMarc R Matrana DOI: 10.4172/2168-9857.1000e121
PDF